Safety and activity of <scp>anti‐CD14</scp> antibody <scp>IC14</scp> (atibuclimab) in <scp>ALS</scp>: Experience with expanded access protocol

Abstract

Administration of IC14 in ALS was safe and well-tolerated in this intermediate-size EAP. Measuring RO guided dosing frequency. Additional placebo-controlled trials are required to determine the efficacy of IC14 in ALS.